MARKET

CHMA

CHMA

Chiasma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.890
+0.040
+1.04%
After Hours: 3.880 -0.01 -0.25% 17:53 02/26 EST
OPEN
3.910
PREV CLOSE
3.850
HIGH
3.930
LOW
3.680
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
7.75
52 WEEK LOW
2.880
MARKET CAP
224.86M
P/E (TTM)
-2.6809
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings
Biotech stocks extended their losses in the week ended Feb. 26 amid continued weakness in the broader market. Earnings came in thick and fast, with a skew of small and midcap companies releasing their quarterly results.
Benzinga · 1d ago
Acromegaly - Pipeline Insight, 2020
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Acromegaly - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+...
Heraldkeepers · 2d ago
Chiasma to Report Fourth Quarter 2020 Results on March 4
Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Thursday, March 4, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter and year ...
GlobeNewswire · 3d ago
Acromegaly Treatment Market Type , Application and Region - Global Trends and Forecast to 2027 By Ameco Research
Comserve · 02/11 05:39
Neuroendocrine Carcinoma Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 09, 2021 (Market Insight Reports) -- The Neuroendocrine Carcinoma Treatment research is an astute report with intricate details for studying appropriate...
Market Insight Reports · 02/09 12:03
Do Institutions Own Chiasma, Inc. (NASDAQ:CHMA) Shares?
Simply Wall St. · 02/06 07:19
Global Acromegaly Treatment Market Size: 2021, Growth, Latest Trends, Industry Share, Top Company Profiles with Sales, Revenues | Expansion Plans, Forecast to 2027
Feb 05, 2021 (The Expresswire) -- The Global “Acromegaly Treatment Market” report offers a detailed knowledge about the market segments and opportunities,...
The Express Wire · 02/05 07:48
Oral Proteins and Peptides Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 03, 2021 (Market Insight Reports) -- The Global Oral Proteins and Peptides Market is estimated to value over USD 7.5 billion by 2027 end with a CAGR of...
Market Insight Reports · 02/03 06:43
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CHMA. Analyze the recent business situations of Chiasma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CHMA stock price target is 13.20 with a high estimate of 18.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 145
Institutional Holdings: 41.25M
% Owned: 71.37%
Shares Outstanding: 57.80M
TypeInstitutionsShares
Increased
31
3.64M
New
25
-1.88M
Decreased
22
3.63M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.05%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
David Stack
President/Chief Executive Officer/Director
Raj Kannan
Chief Financial Officer/Senior Vice President/Treasurer
John Doyle
Executive Vice President
Anand Varadan
Executive Vice President
anand Varadan
Senior Vice President
William Ludlam
Chief Accounting Officer/Vice President - Finance/Vice President - Administration
Drew Enamait
Vice President/General Counsel/Secretary
Lee Giguere
Director
Roni Mamluk
Independent Director
Todd Foley
Independent Director
Bard Geesaman
Independent Director
Scott Minick
Independent Director
John Scarlett
Independent Director
John Thero
  • Dividends
  • Splits
  • Insider Activity
No Data
About CHMA
Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Webull offers kinds of Chiasma Inc stock information, including NASDAQ:CHMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHMA stock methods without spending real money on the virtual paper trading platform.